Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Research & Development: 2016-2025

Historic Research & Development for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to $216.2 million.

  • Ultragenyx Pharmaceutical's Research & Development rose 27.10% to $216.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $734.5 million, marking a year-over-year increase of 9.52%. This contributed to the annual value of $697.9 million for FY2024, which is 7.62% up from last year.
  • Per Ultragenyx Pharmaceutical's latest filing, its Research & Development stood at $216.2 million for Q3 2025, which was up 31.25% from $164.7 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's Research & Development's 5-year high stood at $237.3 million during Q3 2022, with a 5-year trough of $113.2 million in Q2 2021.
  • Its 3-year average for Research & Development is $172.1 million, with a median of $165.7 million in 2023.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Research & Development soared by 109.23% in 2022 and then tumbled by 33.73% in 2023.
  • Quarterly analysis of 5 years shows Ultragenyx Pharmaceutical's Research & Development stood at $123.0 million in 2021, then surged by 38.85% to $170.8 million in 2022, then decreased by 6.00% to $160.6 million in 2023, then increased by 16.95% to $187.8 million in 2024, then rose by 27.10% to $216.2 million in 2025.
  • Its last three reported values are $216.2 million in Q3 2025, $164.7 million for Q2 2025, and $165.8 million during Q1 2025.